METTL3-Mediated m 6 A Modification of FMRP Drives Hepatocellular Carcinoma Progression and Indicates Poor Prognosis
Cancer Biotherapy and Radiopharmaceuticals · 2024
DOI: 10.1089/cbr.2023.0186 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Biotherapy and Radiopharmaceuticals, 2024. Verfasst von Siyuan Fu und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Naval Medical University), Shang…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Methyltransferases, Disease Progression. Die Arbeit nennt 33 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Naval Medical University), Shanghai, China.
ORCID-Profile: Fangming Gu
Zitieren
APA
Fu, S., Sun, D., Wang, Z., Zhu, P., Ding, W., Huang, J., Guo, X., Yang, Y., & Gu, F. (2024). METTL3-Mediated m 6 A Modification of FMRP Drives Hepatocellular Carcinoma Progression and Indicates Poor Prognosis. Cancer Biotherapy and Radiopharmaceuticals. https://doi.org/10.1089/cbr.2023.0186
Vancouver
Fu S, Sun D, Wang Z, Zhu P, Ding W, Huang J, et al. METTL3-Mediated m 6 A Modification of FMRP Drives Hepatocellular Carcinoma Progression and Indicates Poor Prognosis. Cancer Biotherapy and Radiopharmaceuticals. 2024. doi:10.1089/cbr.2023.0186
BibTeX
@article{Fu2024,
author = {Fu, Siyuan and Sun, Dapeng and Wang, Zongyan and Zhu, Peng and Ding, Wenbin and Huang, Jian and Guo, Xinggang and Yang, Yun and Gu, Fangming},
title = {METTL3-Mediated m 6 A Modification of FMRP Drives Hepatocellular Carcinoma Progression and Indicates Poor Prognosis},
journal = {Cancer Biotherapy and Radiopharmaceuticals},
year = {2024},
doi = {10.1089/cbr.2023.0186}
}
EUVIMED